Matches in SemOpenAlex for { <https://semopenalex.org/work/W3004523645> ?p ?o ?g. }
Showing items 1 to 88 of
88
with 100 items per page.
- W3004523645 endingPage "158" @default.
- W3004523645 startingPage "158" @default.
- W3004523645 abstract "158 Background: The multi-kinase inhibitor regorafenib (REGO) and oral fluoropyrimidine TAS-102 (TAS) show efficacies as single agents in treatment of refractory metastatic CRC patients (pts). We conducted a conventional 3+3 dose finding to determine a recommended phase II dose (RP2D) of its combination REGOTAS and efficacy in 3-4.-line. Methods: Eligible patients with ECOG 0-1, measurable mCRC, not amenable to surgery had at least 3rd-line treatments. Prior fluoropyrimidine-based and anti-VEGF (R) combinations were mandatory, and anti-EGFR for RAS WT tumors. TAS was given on days 1-5 and 8-12 (28-days cycle); REGO on days 2-22 (dose levels see table below). The following major AE categories were used to define DLTs if they occurred during the first 2 treatment cycles: any grade ≥3 non-hematologic toxicity (except vomiting, nausea, non-significant lab abnormalities), grade ≥3 hematological toxicities, grade ≥3 bleeding. Tumor response was assessed Q8W as per RECIST1.1. EudraCT 2016-001968-11; NCT03305913. Results: All observed toxicities were consistent with safety profile of individual IMPs. 6 pts were enrolled into each DL1 and DL2 (n=12 in total). One DLT was observed in 1/6 pts in DL1; 2 DLTs in 2/6 pts in DL2. All DLTs were only grade 3 hypertension was well manageable, causality was attributed to REGO. No DLT resulted in treatment discontinuation. Results indicate a RP2D of 25mg/m² TAS-102 BID + 120mg REGO daily. No remissions were observed. Overall disease control rate (DCR) after 8 weeks was promising with 58.3% (DCR of 33.3% for DL1 and 83.3% in DL2) and remarkably better as historical data with 41/44% for REGO/TAS102 alone, respectively (Lancet 2013/NEJM 2015). Conclusions: Toxicities of REGOTAS were consistent with safety profiles of REGO and TAS alone. No additional DLTs were attributed to REGOTAS. Thus, the risk-benefit assessment of REGOTAS was positive. DCR was clinically quite meaningful. Mature PFS and OS will be presented at the meeting. Clinical trial information: NCT03305913. [Table: see text]" @default.
- W3004523645 created "2020-02-14" @default.
- W3004523645 creator A5000482941 @default.
- W3004523645 creator A5000503244 @default.
- W3004523645 creator A5003920642 @default.
- W3004523645 creator A5004228804 @default.
- W3004523645 creator A5004519568 @default.
- W3004523645 creator A5012316751 @default.
- W3004523645 creator A5038131926 @default.
- W3004523645 creator A5055149854 @default.
- W3004523645 creator A5056028552 @default.
- W3004523645 creator A5069953046 @default.
- W3004523645 creator A5070876877 @default.
- W3004523645 creator A5084086757 @default.
- W3004523645 date "2020-02-01" @default.
- W3004523645 modified "2023-10-01" @default.
- W3004523645 title "Regorafenib with TAS-102 (REGOTAS) in metastatic colorectal cancer patients who progressed after at least two standard therapies: Efficacy and safety results of a multicenter phase I study (REMETY)." @default.
- W3004523645 doi "https://doi.org/10.1200/jco.2020.38.4_suppl.158" @default.
- W3004523645 hasPublicationYear "2020" @default.
- W3004523645 type Work @default.
- W3004523645 sameAs 3004523645 @default.
- W3004523645 citedByCount "4" @default.
- W3004523645 countsByYear W30045236452020 @default.
- W3004523645 countsByYear W30045236452023 @default.
- W3004523645 crossrefType "journal-article" @default.
- W3004523645 hasAuthorship W3004523645A5000482941 @default.
- W3004523645 hasAuthorship W3004523645A5000503244 @default.
- W3004523645 hasAuthorship W3004523645A5003920642 @default.
- W3004523645 hasAuthorship W3004523645A5004228804 @default.
- W3004523645 hasAuthorship W3004523645A5004519568 @default.
- W3004523645 hasAuthorship W3004523645A5012316751 @default.
- W3004523645 hasAuthorship W3004523645A5038131926 @default.
- W3004523645 hasAuthorship W3004523645A5055149854 @default.
- W3004523645 hasAuthorship W3004523645A5056028552 @default.
- W3004523645 hasAuthorship W3004523645A5069953046 @default.
- W3004523645 hasAuthorship W3004523645A5070876877 @default.
- W3004523645 hasAuthorship W3004523645A5084086757 @default.
- W3004523645 hasConcept C121608353 @default.
- W3004523645 hasConcept C126322002 @default.
- W3004523645 hasConcept C141071460 @default.
- W3004523645 hasConcept C143998085 @default.
- W3004523645 hasConcept C197934379 @default.
- W3004523645 hasConcept C2776248978 @default.
- W3004523645 hasConcept C2778375690 @default.
- W3004523645 hasConcept C2778715236 @default.
- W3004523645 hasConcept C2780580376 @default.
- W3004523645 hasConcept C2780852908 @default.
- W3004523645 hasConcept C29730261 @default.
- W3004523645 hasConcept C31760486 @default.
- W3004523645 hasConcept C526805850 @default.
- W3004523645 hasConcept C71924100 @default.
- W3004523645 hasConcept C90924648 @default.
- W3004523645 hasConceptScore W3004523645C121608353 @default.
- W3004523645 hasConceptScore W3004523645C126322002 @default.
- W3004523645 hasConceptScore W3004523645C141071460 @default.
- W3004523645 hasConceptScore W3004523645C143998085 @default.
- W3004523645 hasConceptScore W3004523645C197934379 @default.
- W3004523645 hasConceptScore W3004523645C2776248978 @default.
- W3004523645 hasConceptScore W3004523645C2778375690 @default.
- W3004523645 hasConceptScore W3004523645C2778715236 @default.
- W3004523645 hasConceptScore W3004523645C2780580376 @default.
- W3004523645 hasConceptScore W3004523645C2780852908 @default.
- W3004523645 hasConceptScore W3004523645C29730261 @default.
- W3004523645 hasConceptScore W3004523645C31760486 @default.
- W3004523645 hasConceptScore W3004523645C526805850 @default.
- W3004523645 hasConceptScore W3004523645C71924100 @default.
- W3004523645 hasConceptScore W3004523645C90924648 @default.
- W3004523645 hasIssue "4_suppl" @default.
- W3004523645 hasLocation W30045236451 @default.
- W3004523645 hasOpenAccess W3004523645 @default.
- W3004523645 hasPrimaryLocation W30045236451 @default.
- W3004523645 hasRelatedWork W1972179746 @default.
- W3004523645 hasRelatedWork W1995650316 @default.
- W3004523645 hasRelatedWork W2079576335 @default.
- W3004523645 hasRelatedWork W2104761597 @default.
- W3004523645 hasRelatedWork W2156337883 @default.
- W3004523645 hasRelatedWork W2372442000 @default.
- W3004523645 hasRelatedWork W2394317912 @default.
- W3004523645 hasRelatedWork W2528959283 @default.
- W3004523645 hasRelatedWork W2183331092 @default.
- W3004523645 hasRelatedWork W2780730593 @default.
- W3004523645 hasVolume "38" @default.
- W3004523645 isParatext "false" @default.
- W3004523645 isRetracted "false" @default.
- W3004523645 magId "3004523645" @default.
- W3004523645 workType "article" @default.